Avidity Biosciences surges 36% on reports that Novartis may eye a deal, with talks said to be early and interest from other suitors possible.

The Alabama Department of Public Health (ADPH) was recently made aware of a confirmed case of measles in North Alabama in a ...

Oncologists and scientists warn that extensive cuts to mRNA funding will have devastating impacts on cancer vaccine ...

Certain types of biochemical processes can impair the immune system's ability to recognize and kill cancer cells. Purdue ...

The Trump administration may remove COVID-19 vaccines from the U.S. market as RFK Jr.'s allies gain influence at HHS, with a ...

In the past decade there has been significant interest in studying the expression of our genetic code down to the level of single cells, to identify the functions and activities of any cell through ...

After a person survives a heart attack, the heart has a brief window of time in which it can heal if the right circumstances ...

The candidates are sourced from Arnatar’s next-gen RNA discovery engine, dubbed DARGER for dual-functional antisense RNA for ...

Company to Highlight the Role of Precision Diagnostics in Transforming Rare and Undiagnosed Disease CareHOUSTON, Aug. 25, ...

Arnatar is developing ART4, an antisense oligonucleotide that ups the expression of its target protein to treat a rare ...

Scientists have decoded a century-old killer hiding in a preserved lung. New genetic evidence from 1918 reveals the virus was ...

Arnatar Therapeutics, a biotechnology company pioneering RNA-based therapies for severe and underserved diseases, emerges from stealth today and announces that the U.S. Food and Drug Administration ...